<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36008843</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Co-deposition of SOD1, TDP-43 and p62 proteinopathies in ALS: evidence for multifaceted pathways underlying neurodegeneration.</ArticleTitle><Pagination><StartPage>122</StartPage><MedlinePgn>122</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">122</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-022-01421-9</ELocationID><Abstract><AbstractText>Multiple neurotoxic proteinopathies co-exist within vulnerable neuronal populations in all major neurodegenerative diseases. Interactions between these pathologies may modulate disease progression, suggesting they may constitute targets for disease-modifying treatments aiming to slow or halt neurodegeneration. Pairwise interactions between superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TDP-43) and ubiquitin-binding protein 62/sequestosome 1 (p62) proteinopathies have been reported in multiple transgenic cellular and animal models of amyotrophic lateral sclerosis (ALS), however corresponding examination of these relationships in patient tissues is lacking. Further, the coalescence of all three proteinopathies has not been studied in vitro or in vivo to date. These data are essential to guide therapeutic development and enhance the translation of relevant therapies into the clinic. Our group recently profiled SOD1 proteinopathy in post-mortem spinal cord tissues from familial and sporadic ALS cases, demonstrating an abundance of structurally-disordered (dis)SOD1 conformers which become mislocalized within these vulnerable neurons compared with those of aged controls. To explore any relationships between this, and other, ALS-linked proteinopathies, we profiled TDP-43 and p62 within spinal cord motor neurons of the same post-mortem tissue cohort using multiplexed immunofluorescence and immunohistochemistry. We identified distinct patterns of SOD1, TDP43 and p62 co-deposition and subcellular mislocalization between motor neurons of familial and sporadic ALS cases, which we primarily attribute to SOD1 gene status. Our data demonstrate co-deposition of p62 with mutant and wild-type disSOD1 and phosphorylated TDP-43 in familial and sporadic ALS spinal cord motor neurons, consistent with attempts by p62 to mitigate SOD1 and TDP-43 deposition. Wild-type SOD1 and TDP-43 co-deposition was also frequently observed in ALS cases lacking SOD1 mutations. Finally, alterations to the subcellular localization of the three proteins were tightly correlated, suggesting close relationships between the regulatory mechanisms governing the subcellular compartmentalization of these proteins. Our study is the first to profile spatial relationships between SOD1, TDP-43 and p62 pathologies in post-mortem spinal cord motor neurons of ALS patients, previously only studied in vitro. Our findings suggest interactions between these three key ALS-linked proteins are likely to modulate the formation of their respective proteinopathies, and perhaps the rate of motor neuron degeneration, in ALS patients.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trist</LastName><ForeName>Benjamin G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre and School of Medical Sciences (Neuroscience), Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia. benjamin.trist@sydney.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fifita</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogan</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grima</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Bradley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute and the Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>London Neurodegenerative Diseases Brain Bank, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute and the Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute and the Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Sarraj</LastName><ForeName>Safa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>London Neurodegenerative Diseases Brain Bank, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Ian P</ForeName><Initials>IP</Initials><AffiliationInfo><Affiliation>Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Double</LastName><ForeName>Kay L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0001-8712-7781</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre and School of Medical Sciences (Neuroscience), Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia. kay.double@sydney.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02166944</AccessionNumber><AccessionNumber>NCT04057898</AccessionNumber><AccessionNumber>NCT03359538</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Proteinopathy</Keyword><Keyword MajorTopicYN="N">Superoxide dismutase-1</Keyword><Keyword MajorTopicYN="N">TAR DNA-binding protein 43</Keyword><Keyword MajorTopicYN="N">p62/SQSTM1</Keyword></KeywordList><CoiStatement>All authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>23</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36008843</ArticleId><ArticleId IdType="pmc">PMC9404564</ArticleId><ArticleId IdType="doi">10.1186/s40478-022-01421-9</ArticleId><ArticleId IdType="pii">10.1186/s40478-022-01421-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amin A, Perera ND, Beart PM, Turner BJ, Shabanpoor F. Amyotrophic lateral sclerosis and autophagy: dysfunction and therapeutic targeting. Cells. 2020 doi: 10.3390/cells9112413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9112413</ArticleId><ArticleId IdType="pmc">PMC7694295</ArticleId><ArticleId IdType="pubmed">33158177</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkin JD, Farg MA, Soo KY, Walker AK, Halloran M, Turner BJ, Nagley P, Horne MK. Mutant SOD1 inhibits ER-Golgi transport in amyotrophic lateral sclerosis. J Neurochem. 2014;129:190&#x2013;204. doi: 10.1111/jnc.12493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12493</ArticleId><ArticleId IdType="pubmed">24134191</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, Schoenfeld D. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565&#x2013;e574. doi: 10.1212/WNL.0000000000004960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004960</ArticleId><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK. The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci. 2019;13:335. doi: 10.3389/fnins.2019.00335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00335</ArticleId><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Meng P, Zheng Y, Mao Y, Hu F. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem. 2011;116:248&#x2013;259. doi: 10.1111/j.1471-4159.2010.07098.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07098.x</ArticleId><ArticleId IdType="pubmed">21062285</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br J Pharmacol. 2021;178:1298&#x2013;1315. doi: 10.1111/bph.15148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15148</ArticleId><ArticleId IdType="pubmed">32469420</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, Court FA, van Zundert B, Hetz C. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9:1308&#x2013;1320. doi: 10.4161/auto.25188.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.25188</ArticleId><ArticleId IdType="pubmed">23851366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PC, Hsieh YC, Huang CC, Hu CJ. Tamoxifen for amyotrophic lateral sclerosis: a randomized double-blind clinical trial. Medicine (Baltimore) 2020;99:e20423. doi: 10.1097/MD.0000000000020423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000020423</ArticleId><ArticleId IdType="pubmed">32481440</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wang H, Ying Z, Gao Q. Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: the new molecular mechanism of ibudilast and its implication for neuroprotective therapy. Biochem Biophys Res Commun. 2020;526:231&#x2013;238. doi: 10.1016/j.bbrc.2020.03.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.03.051</ArticleId><ArticleId IdType="pubmed">32204915</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, Scaber J, Ababneh N, Lalic T, Weir G, Christian H, Vowles J, Douglas AG, Fletcher-Jones A, Browne C, et al. C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal dementia. Stem Cells. 2016;34:2063&#x2013;2078. doi: 10.1002/stem.2388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2388</ArticleId><ArticleId IdType="pmc">PMC4979662</ArticleId><ArticleId IdType="pubmed">27097283</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, Ajroud-Driss S, Heller S, Sufit R, et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol. 2010;67:739&#x2013;748. doi: 10.1002/ana.22051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22051</ArticleId><ArticleId IdType="pmc">PMC4376270</ArticleId><ArticleId IdType="pubmed">20517935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Dormann D. TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett. 2017;591:1489&#x2013;1507. doi: 10.1002/1873-3468.12646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12646</ArticleId><ArticleId IdType="pubmed">28380257</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell NE, McAlary L, Lum JS, Chisholm CG, Warraich ST, Blair IP, Vine KL, Saunders DN, Yerbury JJ. Ubiquitin homeostasis is disrupted in TDP-43 and FUS cell models of ALS. iScience. 2020;23:101700. doi: 10.1016/j.isci.2020.101700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101700</ArticleId><ArticleId IdType="pmc">PMC7644588</ArticleId><ArticleId IdType="pubmed">33196025</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg K, Graffmo K, Pakkenberg B, Weber M, Nielsen M, Marklund S, Brannstrom T, Andersen PM. Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes. J Neurol Neurosurg Psychiatry. 2019;90:861&#x2013;869. doi: 10.1136/jnnp-2018-319386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319386</ArticleId><ArticleId IdType="pmc">PMC6691870</ArticleId><ArticleId IdType="pubmed">30992335</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, Jacobsson J, Rosquist R, Marklund SL, Brannstrom T. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS ONE. 2010;5:e11552. doi: 10.1371/journal.pone.0011552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011552</ArticleId><ArticleId IdType="pmc">PMC2904380</ArticleId><ArticleId IdType="pubmed">20644736</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Yamanaka K, O&#x2019;Halloran TV, Nukina N. Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis. J Biol Chem. 2008;283:24167&#x2013;24176. doi: 10.1074/jbc.M802083200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M802083200</ArticleId><ArticleId IdType="pmc">PMC3259764</ArticleId><ArticleId IdType="pubmed">18552350</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J, Strom AL, Kilty R, Zhang F, Zhu H. p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis. J Biol Chem. 2007;282:11068&#x2013;11077. doi: 10.1074/jbc.M608787200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M608787200</ArticleId><ArticleId IdType="pubmed">17296612</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J, Strom AL, Kwinter DM, Kilty R, Zhang J, Shi P, Fu W, Wooten MW, Zhu H. Sequestosome 1/p62 links familial ALS mutant SOD1 to LC3 via an ubiquitin-independent mechanism. J Neurochem. 2009;111:1062&#x2013;1073. doi: 10.1111/j.1471-4159.2009.06388.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06388.x</ArticleId><ArticleId IdType="pmc">PMC2766427</ArticleId><ArticleId IdType="pubmed">19765191</ArticleId></ArticleIdList></Reference><Reference><Citation>Guareschi S, Cova E, Cereda C, Ceroni M, Donetti E, Bosco DA, Trotti D, Pasinelli P. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A. 2012;109:5074&#x2013;5079. doi: 10.1073/pnas.1115402109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1115402109</ArticleId><ArticleId IdType="pmc">PMC3324021</ArticleId><ArticleId IdType="pubmed">22416121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S, Mitsui S, Pan L, Otomo A, Kubo M, Sato K, Ono S, Onodera W, Abe K, Chen X, et al. Functional links between SQSTM1 and ALS2 in the pathogenesis of ALS: cumulative impact on the protection against mutant SOD1-mediated motor dysfunction in mice. Hum Mol Genet. 2016;25:3321&#x2013;3340. doi: 10.1093/hmg/ddw180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw180</ArticleId><ArticleId IdType="pubmed">27439389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Yan S, Zhang Z. Maintaining the balance of TDP-43, mitochondria, and autophagy: a promising therapeutic strategy for neurodegenerative diseases. Transl Neurodegener. 2020;9:40. doi: 10.1186/s40035-020-00219-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00219-w</ArticleId><ArticleId IdType="pmc">PMC7597011</ArticleId><ArticleId IdType="pubmed">33126923</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon GS, Shim YM, Lee DY, Kim JS, Kang M, Ahn SH, Shin JY, Geum D, Hong YH, Sung JJ. Pathological modification of TDP-43 in amyotrophic lateral sclerosis with SOD1 mutations. Mol Neurobiol. 2019;56:2007&#x2013;2021. doi: 10.1007/s12035-018-1218-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1218-2</ArticleId><ArticleId IdType="pmc">PMC6394608</ArticleId><ArticleId IdType="pubmed">29982983</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WJ, Ye L, Huang WF, Guo LJ, Xu ZG, Wu HL, Yang C, Liu HF. p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell Mol Biol Lett. 2016;21:29. doi: 10.1186/s11658-016-0031-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11658-016-0031-z</ArticleId><ArticleId IdType="pmc">PMC5415757</ArticleId><ArticleId IdType="pubmed">28536631</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427&#x2013;434. doi: 10.1002/ana.21147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, D'Amico R, Zucchi E, Gessani A, Fini N, Fasano A, Caponnetto C, Chio A, Dalla Bella E, Lunetta C, et al. Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) Medicine (Baltimore) 2018;97:e11119. doi: 10.1097/MD.0000000000011119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011119</ArticleId><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L, Drexler HCA, Wang J, Tripathi P, Distler T, Heisterkamp P, Anderson EN, Kour S, Moraiti A, Maharana S, et al. FUS pathology in ALS is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol. 2019;138:67&#x2013;84. doi: 10.1007/s00401-019-01998-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01998-x</ArticleId><ArticleId IdType="pmc">PMC6570784</ArticleId><ArticleId IdType="pubmed">30937520</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP, Williams KL, Fifita JA, Tarr IS, O'Connor J, Rowe DB, Nicholson GA, Blair IP. The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet. 2017 doi: 10.1111/cge.12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12973</ArticleId><ArticleId IdType="pubmed">28105640</ArticleId></ArticleIdList></Reference><Reference><Citation>Medinas DB, Rozas P, Martinez Traub F, Woehlbier U, Brown RH, Bosco DA, Hetz C. Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2018;115:8209&#x2013;8214. doi: 10.1073/pnas.1801109115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1801109115</ArticleId><ArticleId IdType="pmc">PMC6094144</ArticleId><ArticleId IdType="pubmed">30038021</ArticleId></ArticleIdList></Reference><Reference><Citation>Medinas DB, Valenzuela V, Hetz C. Proteostasis disturbance in amyotrophic lateral sclerosis. Hum Mol Genet. 2017;26:R91&#x2013;R104. doi: 10.1093/hmg/ddx274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx274</ArticleId><ArticleId IdType="pubmed">28977445</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsui S, Otomo A, Nozaki M, Ono S, Sato K, Shirakawa R, Adachi H, Aoki M, Sobue G, Shang HF, et al. Systemic overexpression of SQSTM1/p62 accelerates disease onset in a SOD1(H46R)-expressing ALS mouse model. Mol Brain. 2018;11:30. doi: 10.1186/s13041-018-0373-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-018-0373-8</ArticleId><ArticleId IdType="pmc">PMC5975400</ArticleId><ArticleId IdType="pubmed">29843805</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno Y, Amari M, Takatama M, Aizawa H, Mihara B, Okamoto K. Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis. J Neurol Sci. 2006;249:13&#x2013;18. doi: 10.1016/j.jns.2006.05.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2006.05.060</ArticleId><ArticleId IdType="pubmed">16820172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Suzuki G, Tanaka Y, Kametani F, Hirai S, Okado H, Miyashita T, Saitoe M, Akiyama H, Masai H, et al. Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1delta triggers mislocalization and accumulation of TDP-43. J Biol Chem. 2016;291:5473&#x2013;5483. doi: 10.1074/jbc.M115.695379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.695379</ArticleId><ArticleId IdType="pmc">PMC4786690</ArticleId><ArticleId IdType="pubmed">26769969</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankiv S, Lamark T, Bruun JA, Overvatn A, Bjorkoy G, Johansen T. Nucleocytoplasmic shuttling of p62/SQSTM1 and its role in recruitment of nuclear polyubiquitinated proteins to promyelocytic leukemia bodies. J Biol Chem. 2010;285:5941&#x2013;5953. doi: 10.1074/jbc.M109.039925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.039925</ArticleId><ArticleId IdType="pmc">PMC2820819</ArticleId><ArticleId IdType="pubmed">20018885</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR, Cashman NR. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e35050. doi: 10.1371/journal.pone.0035050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0035050</ArticleId><ArticleId IdType="pmc">PMC3320864</ArticleId><ArticleId IdType="pubmed">22493728</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BR, Lim NK, McAllum EJ, Donnelly PS, Hare DJ, Doble PA, Turner BJ, Price KA, Lim SC, Paterson BM, et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2014;34:8021&#x2013;8031. doi: 10.1523/JNEUROSCI.4196-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4196-13.2014</ArticleId><ArticleId IdType="pmc">PMC6608261</ArticleId><ArticleId IdType="pubmed">24899723</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson J, Sanelli T, Xiao S, Yang W, Horne P, Hammond R, Pioro EP, Strong MJ. Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci Lett. 2007;420:128&#x2013;132. doi: 10.1016/j.neulet.2007.03.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2007.03.066</ArticleId><ArticleId IdType="pubmed">17543992</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, Oregan JP, Deng HX, et al. Mutations in Cu/Zn Superoxide-dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Soo KY, Halloran M, Sundaramoorthy V, Parakh S, Toth RP, Southam KA, McLean CA, Lock P, King A, Farg MA, et al. Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS. Acta Neuropathol. 2015;130:679&#x2013;697. doi: 10.1007/s00401-015-1468-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1468-2</ArticleId><ArticleId IdType="pubmed">26298469</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21:1332&#x2013;1340. doi: 10.1038/s41593-018-0235-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0235-9</ArticleId><ArticleId IdType="pmc">PMC6432913</ArticleId><ArticleId IdType="pubmed">30250260</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134:187&#x2013;205. doi: 10.1007/s00401-017-1709-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1709-7</ArticleId><ArticleId IdType="pmc">PMC5508034</ArticleId><ArticleId IdType="pubmed">28401333</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15:45. doi: 10.1186/s13024-020-00397-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaramoorthy V, Walker AK, Yerbury J, Soo KY, Farg MA, Hoang V, Zeineddine R, Spencer D, Atkin JD. Extracellular wildtype and mutant SOD1 induces ER-Golgi pathology characteristic of amyotrophic lateral sclerosis in neuronal cells. Cell Mol Life Sci. 2013;70:4181&#x2013;4195. doi: 10.1007/s00018-013-1385-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1385-2</ArticleId><ArticleId IdType="pubmed">23765103</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji K, Zhang HX, Mori F, Kakita A, Takahashi H, Wakabayashi K. p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J Neurosci Res. 2012;90:2034&#x2013;2042. doi: 10.1002/jnr.23081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23081</ArticleId><ArticleId IdType="pubmed">22674379</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist BG, Genoud S, Roudeau S, Rookyard A, Abdeen A, Cottam V, Hare DJ, White M, Altvater J, Fifita JA, et al. Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain. 2022 doi: 10.1093/brain/awac165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac165</ArticleId><ArticleId IdType="pubmed">35512359</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist BG, Hilton JB, Hare DJ, Crouch PJ, Double KL. Superoxide dismutase 1 in health and disease: how a frontline antioxidant becomes neurotoxic. Angew Chem Int Ed Engl. 2020 doi: 10.1002/anie.202000451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202000451</ArticleId><ArticleId IdType="pmc">PMC8247289</ArticleId><ArticleId IdType="pubmed">32144830</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JR, Trias E, Beilby PR, Lopez NI, Labut EM, Bradford CS, Roberts BR, McAllum EJ, Crouch PJ, Rhoads TW, et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol Dis. 2016;89:1&#x2013;9. doi: 10.1016/j.nbd.2016.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.01.020</ArticleId><ArticleId IdType="pmc">PMC4785045</ArticleId><ArticleId IdType="pubmed">26826269</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeineddine R, Farrawell NE, Lambert-Smith IA, Yerbury JJ. Addition of exogenous SOD1 aggregates causes TDP-43 mislocalisation and aggregation. Cell Stress Chaperones. 2017;22:893&#x2013;902. doi: 10.1007/s12192-017-0804-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-017-0804-y</ArticleId><ArticleId IdType="pmc">PMC5655364</ArticleId><ArticleId IdType="pubmed">28560609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>